Jonathan M. Meyer, MD

  • 14Articles
  • 45KReads
  • 1997–2025Active
  • 19Collaborators
  • 655Citations

About

Jonathan M. Meyer, MD, is affiliated with the Department of Psychiatry at the University of California San Diego. With a publication record spanning from 1997 to 2025, Meyer has contributed extensively to the study of schizophrenia and schizoaffective disorders, focusing on antipsychotic treatment mechanisms, safety, and metabolic side effects. His work also addresses related areas including depression, metabolic disorders, hepatitis, movement disorders, and neurology. Meyer has collaborated frequently with co-authors such as Edward C. Lauterbach, George M. Simpson, Anissa Abi-Dargham, Ashok Malla, and Christoph U. Correll.

Publications

JCP
Clozapine Monitoring in the Post-REMS World: Some Guidance for Clinicians
ASCP Corner

Clozapine Monitoring in the Post-REMS World: Some Guidance for Clinicians

May 5, 2025

While the abolition of REMS for clozapine expands access, the change could create confusion. Among the most relevant examples are mismatches between FDA recommendations for lifetime monitoring and the...
,
JCP
Non-Dopaminergic Mechanisms for Schizophrenia Symptom Management
Educational Activity

Non-Dopaminergic Mechanisms for Schizophrenia Symptom Management

August 7, 2023

Next generation therapeutics that work well, are better tolerated, and lead to improved outcomes may offer a different treatment approach for patients with schizophrenia.
,
JCP
Educational Activity

The Glutamate Hypothesis of Schizophrenia

July 15, 2014

JCP
Commentary

Schizophrenia: The Role of Dopamine and Glutamate

February 19, 2014

,
JCP
How to Interpret Findings Concerning Newly Approved Antipsychotic Agents: Clinical Implications of the Lurasidone PEARL 2 Study
InfoPack

How to Interpret Findings Concerning Newly Approved Antipsychotic Agents: Clinical Implications of the Lurasidone PEARL 2 Study

August 15, 2012

, , , et al
JCP
Original Research

The Moderating Impact of Ethnicity on Metabolic Outcomes During Treatment With Olanzapine and Aripiprazole in Patients With Schizophrenia

December 16, 2009

, , , et al
JCP
Educational Activity

Sexual Dysfunction in Patients Treated With Atypical Antipsychotics

September 30, 2008

JCP
Article

Antipsychotic Safety and Efficacy Concerns

December 14, 2007

JCP
Article

Strategies for the Long-Term Treatment of Schizophrenia: Real-World Lessons From the CATIE Trial

January 15, 2007

JCP
Original Research

Prevalence of Hepatitis A, Hepatitis B, and HIV Among Hepatitis C-Seropositive State Hospital Patients: Results From Oregon State Hospital

May 15, 2003

JCP
Original Research

A Retrospective Comparison of Weight, Lipid, and Glucose Changes Between Risperidone- and Olanzapine-Treated Inpatients: Metabolic Outcomes After 1 Year

May 12, 2002

JCP
Article

Effects of Atypical Antipsychotics on Weight and Serum Lipid Levels

January 14, 2001

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe